The Problem:

Cancers of the liver affect 1.2 million globally people every year. Additional treatment options are required for these patients.

Our Solution:

We are investigating a percutaneous targeted, whole-organ therapy that delivers high-dose chemotherapy directly to the liver with blood filtration to reduce systemic toxicity and related side effects (Melphalan/Hepatic Delivery System).

Our Team:

Dedication and commitment to improving patients’ lives

    Delcath are investigating the potential for our therapy in two key areas:

    1. FOCUS 301A Registration study—for patients with ocular melanoma metastatic to the liver.

    2. ALIGN Phase 3 study to investigate Melphalan/Hepatic Delivery System vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

    More Information

    More Information

    For more information contact Delcath at +1 212.489.2100 or medaffairs@delcath.com